Weekly Digest – May 2025 Weekly Digest – May 2025 29 May 2025: China’s HER2-targeted ADC Trastuzumab Rezetecan gains NMPA approval for HER2-mutant NSCLC China approved Trastuzumab rezetecan, its first domestically developed antibody-drug conjugate (ADC), for treating HER2-mutant advanced non-small […]
Contact:
info@ciscientists.com
+1-908-212-7484
Optimal Dose
For a subscription, please provide your email id